Assembly Biosciences Inc.

(ASMB) Trade

By |

Profile

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Contact Information

Website: www.assemblybio.com
Email: info@assemblybio.com
Main Phone: +1 833 509-4583
Address: 331 Oyster Point Blvd
Address 2: Fourth Floor
State: CA
City / Town: South San Francisco
Country: US
Postal Code: 94080

Issuer Information

Exchange: NGS
CEO: John G. McHutchison
Employees: 120
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Contact Information

Website: www.assemblybio.com
Email: info@assemblybio.com
Main Phone: +1 833 509-4583
Address: 331 Oyster Point Blvd
Address 2: Fourth Floor
State: CA
City / Town: South San Francisco
Country: US
Postal Code: 94080

Issuer Information

Exchange: NGS
CEO: John G. McHutchison
Employees: 120
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 16.25 $ 0.09 (0.56%)
Last Price 16.25 Change $ 0.09 Change % 0.56 Tick N/A
Bid 15.00 Bid Size 100.00 Ask 25.84 Ask Size 100.00
Open 16.05 High 16.63 Low 16.01 Prev Close 16.16
Last Trade Volume 135,243 52 Wk Hi 27.85 52 Wk Low 8.14
Market Cap 533.9 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 32,854,914.00 EPS (TTM) -2.51 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 18
Number of Buys 2 9
Number of Sells 2 9
Net Activity 0 24000
Last 10 Buys Shares
Derek Small 1,000
Derek Small 1,000
Russell H. Ellison 1,000
David J. Barrett 1,000
Russell H. Ellison 1,000
David J. Barrett 1,000
Russell H. Ellison 1,000
Russell H. Ellison 1,000
David J. Barrett 1,000
Russell H. Ellison 1,000
Last 10 Sell Shares
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
William R. Ringo 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 75 75 75 75
Low Target Price Estimate 42 42 42 42
Mean Target Price Estimate 55.67 55.67 55.67 55.67
Standard Deviation 17.21 17.21 17.21 17.21
Date of Most Recent Estimate 05/08/18 05/08/18 05/08/18 05/08/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 2 2 2
Moderate Buy 0 0 0 0
Hold 2 2 2 2
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2 2 2 2